Literature DB >> 20596597

Suppression of cell death by the secretory form of N-terminal ERC/mesothelin.

Tegexibaiyin Wang1, Kazunori Kajino, Masaaki Abe, Ke Tan, Masumi Maruo, Guodong Sun, Yoshiaki Hagiwara, Masahiro Maeda, Okio Hino.   

Abstract

ERC/mesothelin is highly expressed in malignant mesothelioma, pancreatic cancer, and ovarian cancer. It is cleaved to a 30 kDa N-terminal secretory form (N-ERC) and a 40 kDa C-terminal membranous form (C-ERC). Several functions have been reported for full-length ERC (full-ERC) and C-ERC/mesothelin, such as in cell adhesion and invasion, stimulation of cell proliferation, and the suppression of cell death. However, there have been no studies to date on the function of secretory N-ERC, despite the fact that it is abundantly secreted into the sera of mesothelioma patients. In this study, we investigated whether N-ERC could function as a secretory factor to stimulate tumor progression. Full-, N, or C-ERC was overexpressed in the human hepatocellular carcinoma cell line Huh7 that lacks endogenous expression of ERC/mesothelin. Changes in the rates of cell proliferation and cell death were determined, and the state of signal transducers was examined using various endpoints: total cell counts, trypan blue exclusion rate, BrdU incorporation rate, TUNEL assay, and the phosphorylation of ERK1/2 and Stat3. In cells overexpressing N-ERC, phosphorylation of ERK1/2 was enhanced and the rate of cell death decreased, leading to the increase of cell number. The culture medium containing the secretory N-ERC also had the activity to increase the number of cells. Our data suggested that one of the full-ERC functions reported previously was mediated by the secretory N-ERC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596597     DOI: 10.3892/ijmm_00000451

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.

Authors:  Stefan S Kachala; Adam J Bograd; Jonathan Villena-Vargas; Kei Suzuki; Elliot L Servais; Kyuichi Kadota; Joanne Chou; Camelia S Sima; Eva Vertes; Valerie W Rusch; William D Travis; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

Review 2.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

3.  Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Authors:  Jingli Zhang; Shuo Qiu; Yujian Zhang; Maria Merino; Patricia Fetsch; Itzhak Avital; Armando Filie; Ira Pastan; Raffit Hassan
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

Review 4.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

5.  C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.

Authors:  Futoshi Kawamata; Shigenori Homma; Hirofumi Kamachi; Takahiro Einama; Yasutaka Kato; Masumi Tsuda; Shinya Tanaka; Masahiro Maeda; Kazunori Kajino; Okio Hino; Norihiko Takahashi; Toshiya Kamiyama; Hiroshi Nishihara; Akinobu Taketomi; Satoru Todo
Journal:  J Gastroenterol       Date:  2013-03-20       Impact factor: 7.527

Review 6.  Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Authors:  Sabrina Lagniau; Kevin Lamote; Jan P van Meerbeeck; Karim Y Vermaelen
Journal:  Oncotarget       Date:  2017-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.